Health & Fitness
Health and Fitness
Health and Fitness
Thu, May 13, 2010
Wed, May 12, 2010 Nutra Pharma Announces Publication of Research Report by Grass Roots Research and Distribution, Inc.
CORAL SPRINGS, FL--(Marketwire - May 12, 2010) - Nutra Pharma Corp. (
The publication from Grass Roots Research and Distribution, Inc., which was commissioned by Nutra Pharma, focuses on the company's current drug development initiatives, including the company's leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company's recent launch of [ Cobroxin ] and [ Nyloxin ], treatments for chronic pain.
A PDF of the research report can be accessed at: [ http://www.grassrootsrd.com/grassrootsrd/Reports/Nutra_Pharma_Corp_05_12_2010.pdf ]
About Grass Roots Research and Distribution, Inc.
The Grass Roots Research and Cohen Research brand names are the worldwide Gold Standard for micro cap/small cap research. Grass Roots has raised the art of fundamental securities research by forecasting the three statements and valuing all of its companies in three cases over a 5 year time period. Grass Roots distributes in-depth stock market research reports that highlight the company's market opportunity, technology, management, competition and other key differentiators that may affect their short and long term valuation.
[ http://www.grassrootsrd.com ]
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.
[ http://www.NutraPharma.com ]
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the publication of the research report by Grass Roots Research and Distribution, Inc. should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at [ www.sec.gov ]. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
